0.72
+0.01369998(+1.94%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.73 |
| Day High | 0.74 |
| Day Low | 0.7 |
| 52-Week High | 1.87 |
| 52-Week Low | 0.54 |
| Volume | 93,176 |
| Average Volume | 127,233 |
| Market Cap | 8.39M |
| PE | -0.48 |
| EPS | -1.5 |
| Moving Average 50 Days | 0.9 |
| Moving Average 200 Days | 0.85 |
| Change | 0.01 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $8.16 as of December 25, 2025 at a share price of $0.72. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $42.35 as of December 25, 2025 at a share price of $0.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
GlobeNewswire Inc.
Dec 18, 2025 1:45 PM GMT
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and v
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
GlobeNewswire Inc.
Dec 04, 2025 2:00 PM GMT
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA app
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
GlobeNewswire Inc.
Dec 02, 2025 1:45 PM GMT
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high